Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.
Dec 10, 2014 at 3:20 PM
Oppenheimer 25th Annual Healthcare Conference
Dec 18, 2014
2014 Analyst Day